Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial

Author(s):
Bayani, J.; Yao, C.Q.; Quintayo, M.A.; Haider, S.; Brookes, C.L.; Yan, F.; Velde, C.J.H. van de (0000-0003-0104-1800); Hasenburg, A.; Kieback, D.G.; Markopoulos, C.; Dirix, L.; Seynaeve, C.; Boutros, P.C.; Rea, D.W.; Bartlett, J.M.S.
Published
2016
Publication type
Article / Letter to editor
Date issued
2016-02-15
Language
English
Is part of
Cancer Research
hdl
1887/114002
doi
10.1158/1538-7445.SABCS15-P2-08-29